Cambridge biotech tracker · Cambridge
Enveric Biosciences
Listed on Nasdaq as ENVB, filed under SEC industry code 2834 (pharmaceutical preparations). Fiscal year ends in December. Numbers below are from the company’s own SEC filings through Q2 '26.
- Cash & investments
- —
- Q2 '26 · Jun 29, 2026
- Burn per quarter
- $2.1M
- avg. operating cash flow, 4 qtrs
- Runway
- —
- Not computable
- Net loss
- $3.0M
- Q2 '26
- R&D expense
- $1.4M
- 45% of opex
- Raised, last 4 qtrs
- +$14.0M
- net financing cash flow
Not reported in a standard XBRL tag for this company.
Operating cash flow
Per quarter; below zero is burn
R&D expense
Per quarter
The controller’s read
What the filings say.
Generated from the numbers above using the same questions I ask when I open a client’s books: how long the cash lasts, what is driving the gap between loss and burn, and where the accounting judgment sits.
Get this read on your companyR&D is 45% of operating expenses
$1.4M of R&D against $3.0M of total operating expenses in Q2 '26, with G&A at $1.6M. For a clinical-stage company, the accounting questions live inside that R&D line: CRO and CMC accruals, milestone recognition, and what gets capitalized versus expensed under ASC 730.
Going-concern language in the 10-Q filed May 14, 2026
The filing contains definite substantial-doubt language, the conclusion of an ASC 205-40 evaluation that cash may not cover twelve months from the issuance date without additional financing or cost actions. Read the liquidity note in the filing for management's plans and whether they are considered probable.
Accumulated deficit of $120M
Total losses since inception. It is also roughly the size of the net operating loss carryforward the tax provision has to track, subject to Section 382 limits after each ownership change.
Cash-only balance shown
This company either holds no marketable securities or tags them under a name the tracker does not read. If the 10-Q reports a larger cash-and-investments figure, that figure is the right one.
Quarterly detail, eight quarters
| Quarter | Cash & inv. | Op. cash flow | Net loss | R&D | G&A | Revenue | Stock comp | Financing |
|---|---|---|---|---|---|---|---|---|
| Q3 '24 · Sep 29, 24 | — | −$927K | −$2.1M | $803K | $1.2M | — | $369K | $518K |
| Q4 '24 · Dec 30, 24 | — | −$1.3M | $16.0M | $967K | $2.1M | — | $379K | $463K |
| Q1 '25 · Mar 30, 25 | — | −$2.4M | −$2.2M | $746K | $1.4M | — | $193K | $4.4M |
| Q2 '25 · Jun 29, 25 | — | −$1.9M | −$2.5M | $1.3M | $1.2M | — | $206K | $449K |
| Q3 '25 · Sep 29, 25 | — | −$2.1M | −$1.9M | $402K | $1.4M | — | $187K | $3.0M |
| Q4 '25 · Dec 30, 25 | — | −$1.8M | $18.7M | $372K | $1.8M | — | $62K | $2.7M |
| Q1 '26 · Mar 30, 26 | — | −$2.3M | −$1.6M | $346K | $1.2M | — | $89K | $2.5M |
| Q2 '26 · Jun 29, 26 | — | −$2.4M | −$3.0M | $1.4M | $1.6M | — | $125K | $5.8M |
Source: SEC EDGAR XBRL company facts, latest filed value for each period. Fourth quarters are derived from annual less nine-month figures; quarterly cash flows are derived from year-to-date amounts. Not investment advice. If a figure disagrees with the filing, the filing is right.